A phase-II clinical trial in advanced melanoma showed that combining TriMix-matured moDCs presenting melanoma-associated antigens with ipilumab, an antagonistic CTLA4 antibody, resulted in a 6-month disease control rate of 51%, with an overall tumor response rate of 38% (59). The gene discussed is CTLA4; the disease is melanoma.